[ad_1]
The announcement comes after the company conducted its latest Phase 3 tests on a total of 44,000 people, Bloomberg writes.
Eight of those vaccinated contracted the infection.
Tests show that a total of 170 people in the study were infected with COVID-19, of whom eight had been treated with the active vaccine. The rest, 162, had received a placebo. Of the ten people who developed severe symptoms, one had received the vaccine.
According to drug companies, the results mean the vaccine is 95 percent effective.
According to drug companies, the side effects were mild and passed quickly. However, 3.7 percent of the test subjects who received the vaccine suffered from fatigue.
Protection for older key factor
According to Pfizer-Biontech, the vaccine has now also been shown to be 94 percent effective even in the elderly, which is described as a deal breaker.
– 94% protection for the elderly is essential. This is the proof we need to make sure the weakest people are protected, Andrew Hill, a pharmaceutical researcher at the University of Liverpool, told Reuters.
Request approval within a few days
Previous data presented last week showed the vaccine was 90 percent effective. The improved efficacy and new information about the vaccine’s safety means that Pfizer and Biontech can now take the next step in obtaining approval for the vaccine.
According to the companies, they will apply for an approval for the vaccine from the US Food and Drug Administration (FDA) within a few days. The authority is expected to address the approval issue in mid-December.
